Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Phase 1 Recruiting 190 enrolled Dizal Pharmaceuticals

Non-randomizedSequentialOpen-labelTreatment

Summary

This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.

Timeline

Start: 2024-06-12
Primary completion: 2026-12-30
Completion: 2028-07-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DZD6008	Unknown	20 mg	Oral
Subject	DZD6008	Unknown	40 mg	Oral
Subject	DZD6008	Unknown	60 mg	Oral
Subject	DZD6008	Unknown	90 mg	Oral
Subject	DZD6008	Unknown	120 mg	Oral
Subject	DZD6008	Unknown	150 mg	Oral

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Summary

Timeline

Drugs

Indications